-
RE: Pharyngeal Constrictor Muscle Sparing in Head and Neck Radiotherapy Clin. Oncol. (IF 3.4) Pub Date : 2024-04-06 O. Paetkau, S. Weppler, J. Kwok, H.C. Quon, C. Gomes da Rocha, W. Smith, E. Tchistiakova, C. Kirkby
-
Dosimetric Impact of Delineation and Motion Uncertainties on the Heart and Substructures in Lung Cancer Radiotherapy Clin. Oncol. (IF 3.4) Pub Date : 2024-04-04 V. Chin, R.N. Finnegan, P. Chlap, L. Holloway, D.I. Thwaites, J. Otton, G.P. Delaney, S.K. Vinod
Delineation variations and organ motion produce difficult-to-quantify uncertainties in planned radiation doses to targets and organs at risk. Similar to manual contouring, most automatic segmentation tools generate single delineations per structure; however, this does not indicate the range of clinically acceptable delineations. This study develops a method to generate a range of automatic cardiac
-
Conducting a National RT-QI Project – Challenges and Opportunities Clin. Oncol. (IF 3.4) Pub Date : 2024-03-29 A. Vaandering, Y. Lievens, the Belgian College for Physicians in Radiation Oncology
Over the past decade, there has been an increased interest in defining and monitoring quality indicators (QI) in the field of oncology including the field of radiation oncology. The comprehensive gathering and analysis of QIs on a multicentric scale offer valuable insights into identifying gaps in clinical practice and fostering continuous improvement. This article delineates the evolution and results
-
Advancing the Paradigm: Oligometastatic Disease and the Impact of Stereotactic Ablative Body Radiotherapy Clin. Oncol. (IF 3.4) Pub Date : 2024-03-26 D. Shor, V. Khoo, K.T. Jayaprakash
-
Multi-center Dose Prediction Using Attention-aware Deep learning Algorithm Based on Transformers for Cervical Cancer Radiotherapy Clin. Oncol. (IF 3.4) Pub Date : 2024-03-26 Z. Wu, X. Jia, L. Lu, C. Xu, Y. Pang, S. Peng, M. Liu, Y. Wu
Accurate dose delivery is crucial for cervical cancer volumetric modulated arc therapy (VMAT). We aimed to develop a robust deep-learning (DL) algorithm for fast and accurate dose prediction of cervical cancer VMAT in multicenter datasets and then explore the feasibility of the DL algorithm to endometrial cancer VMAT with different prescriptions. We proposed the AtTranNet algorithm for three-dimensional
-
Service Improvements and Workload Increases: Royal College of Radiologists (RCR) Re-Audit of Curative Intent Radiotherapy for Non-Small Cell Lung Cancer (NSCLC) Clin. Oncol. (IF 3.4) Pub Date : 2024-03-26 J. McAleese, K. Drinkwater, Collaborating Author Group, A. Bedair, A. Williams, A. James, A. Visioli, A. Sykes, A. Mitra, A. Haridass, A. Gore, A. Mirza, C. Stilwell, D. Sherriff, E. Wingate, H. Bainbridge, H. Ariyaratne, I. Phillips, J. Sham, J. Clarke, J. Pang, J. Brady, J. Tay, J. Frew, J. Adams, K. Thippu Jayaprakash, K. Tarver, L. Harihar, M. Churn, M. Griffin, M. Osborne, M. Button, M. Panades
The Royal College of Radiologists (RCR) audit of radical radiotherapy (RR) for patients with non-small cell lung cancer (NSCLC) in 2013 concluded that there was under-treatment compared to international comparators and marked variability between cancer networks. Elderly patients were less likely to receive guideline recommended treatments. Access to technological developments was low. Various national
-
Unveiling Disparities: Exploring Differential Attainment in Postgraduate Training Within Clinical Oncology Clin. Oncol. (IF 3.4) Pub Date : 2024-03-19 Z. Iyizoba-Ebozue, A. Fatimilehin, M. Kayani, A. Khan, M. McMahon, S. Stewart, C. Croney, K. Sritharan, M. Khan, M. Obeid, O. Igwebike, R. Batool, R. A-Hakim, T. Aghadiuno, V. Ruparel, K. O'Reilly
Differential attainment (DA) in post graduate medical training is a recognised challenge and refers to unexplained variation across groups when split by several protected characteristics. The Royal College of Radiology is committed to fostering diversity, inclusivity, and equality with the goal of narrowing existing gaps and improving training outcomes. This was a mixed methods study aiming to understand
-
Neoadjuvant Chemotherapy in Locally Advanced Sinonasal Teratocarcinosarcoma a Rare Malignancy: An Audit From an Academic Tertiary Care Centre in India Clin. Oncol. (IF 3.4) Pub Date : 2024-03-19 Z. Peelay, S. Saha, V. Patil, N. Menon, A. Singh, M. Shah, A. Sahu, A. Ubharay, O.R. Chowdhury, K. Prabhash, V. Noronha
Sinonasal teratocarcinosarcomas (SNTCS) are rare sinonasal malignancies, the incidence of which is less than 1% of all tumors. There is limited data available on SNTCS's, often as case reports and small case series. The management of SNTCS is complicated because of its location, locally aggressive biology, difficulty in achieving complete resection, and limited data on chemotherapy in these malignancies
-
Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience Clin. Oncol. (IF 3.4) Pub Date : 2024-03-19 S. Armstrong, A. Makris, K. Belessiotis-Richards, M. Abdul-Latif, P. Ostler, N. Shah, D. Miles, Y.M. Tsang
Evidence shows stereotactic ablative body radiotherapy (SABR) is used as a non-invasive ablative therapy in the treatment of multisite oligometastatic (OM) and oligoprogressive (OP) diseases originating from metastatic breast cancer. This study aims to report the treatment outcomes and to investigate what factors that are prognostic in terms of local control, progression-free survival (PFS) and overall
-
An Overview of Real-World Data Infrastructure for Cancer Research Clin. Oncol. (IF 3.4) Pub Date : 2024-03-19 G. Price, N. Peek, I. Eleftheriou, K. Spencer, L. Paley, J. Hogenboom, J. van Soest, A. Dekker, M. van Herk, C. Faivre-Finn
There is increasing interest in the opportunities offered by Real World Data (RWD) to provide evidence where clinical trial data does not exist, but access to appropriate data sources is frequently cited as a barrier to RWD research. This paper discusses current RWD resources and how they can be accessed for cancer research. There has been significant progress on facilitating RWD access in the last
-
A Single-Institution Review of the Use of Radiation in the Adjuvant and Definitive Management of Keloids Clin. Oncol. (IF 3.4) Pub Date : 2024-03-18 J. Fernandes, D. Liao, A. Dasgupta, M.N. Tsao, E.A. Barnes
Many individuals suffer from keloids that are refractory to standard treatment modalities, including surgical excision alone. Radiation therapy can be used to reduce the risk of recurrent keloids post-operatively, as well as be used as primary treatment for keloids not amenable to surgical resection. The purpose of this study was to review our institutional experience of radiation therapy for keloid
-
Systematic Review of Hypofractionated Radiation Therapy for the Treatment of Oesophageal Squamous Cell Carcinoma and Oesophageal Adenocarcinoma Clin. Oncol. (IF 3.4) Pub Date : 2024-03-18 C. Sanghera, D.P. McClurg, C.M. Jones
-
Prehabilitation reduces hospital admissions for patients with advanced lung cancer Clin. Oncol. (IF 3.4) Pub Date : 2024-03-18 Iain Phillips, Abi Walton, Colin Barrie, Melanie Mackean
-
Reducing Salivary Toxicity with Adaptive Radiotherapy (ReSTART): A Randomized Controlled Trial Comparing Conventional IMRT to Adaptive IMRT in Head and Neck Squamous Cell Carcinomas Clin. Oncol. (IF 3.4) Pub Date : 2024-03-18 S. Ghosh Laskar, S. Sinha, A. Kumar, A. Samanta, S. Mohanty, S. Kale, F. Khan, S. Lewis Salins, V. Murthy
The utility of Adaptive Radiotherapy (ART) in Head and Neck Squamous Cell Carcinoma (HNSCC) remains to be ascertained. While multiple retrospective and single-arm prospective studies have demonstrated its efficacy in decreasing parotid doses and reducing xerostomia, adequate randomized evidence is lacking. ReSTART (Reducing Salivary Toxicity with Adaptive Radiotherapy) is an ongoing phase III randomized
-
The Impact of Dose Rate on the Tumor Microenvironment Using Flattening-filter-free Beams Clin. Oncol. (IF 3.4) Pub Date : 2024-03-18 M.T. Yilmaz, A. Gok, M.E. Gedik, A. Caglayan, F.Y. Yedekci, S. Aydin Dilsiz, G. Gunaydin, A. Akyol, P. Hurmuz
-
Component Patterns and Survival Outcomes in Patients with Mixed Malignant Ovarian Germ Cell Tumors: A Retrospective Cohort Study Clin. Oncol. (IF 3.4) Pub Date : 2024-03-16 S. Li, R. Zhang, X. Zhang, T. Zhang, D. Cao, Y. Xiang, J. Yang
To evaluate the component patterns and risk stratification in patients with mixed malignant ovarian germ cell tumors (mMOGCT). A retrospective study of 70 mMOGCT patients treated in our hospital between 2000 and 2022 was conducted. The recurrence-free survival (RFS), disease-specific survival (DSS), and risk stratification systems based on scoring the identified prognostic factors were assessed. Yolk
-
Federated Learning Survival Model and Potential Radiotherapy Decision Support Impact Assessment for Non–small Cell Lung Cancer Using Real-World Data Clin. Oncol. (IF 3.4) Pub Date : 2024-03-16 M. Field, S. Vinod, G.P. Delaney, N. Aherne, M. Bailey, M. Carolan, A. Dekker, S. Greenham, E. Hau, J. Lehmann, J. Ludbrook, A. Miller, A. Rezo, J. Selvaraj, J. Sykes, D. Thwaites, L. Holloway
The objective of this study was to develop a two-year overall survival model for inoperable stage I-III non–small cell lung cancer (NSCLC) patients using routine radiation oncology data over a federated (distributed) learning network and evaluate the potential of decision support for curative versus palliative radiotherapy. A federated infrastructure of data extraction, de-identification, standardisation
-
Shared Decision Making in Oncology Care: Translating to Clinical Practice Clin. Oncol. (IF 3.4) Pub Date : 2024-03-15 C. Holden, A. Keen, A. Harle, I.S. Boon
-
North-South Divide: Chemo-Immunotherapy Combination in Head and Neck Squamous Cell Cancer (HNSCC) Clin. Oncol. (IF 3.4) Pub Date : 2024-03-15 I.S. Boon, C.S. Boon, K. Oguejiofor, S. Ramkumar
-
How Long Does Contouring Really Take? Results of the Royal College of Radiologists Contouring Surveys Clin. Oncol. (IF 3.4) Pub Date : 2024-03-15 E. Montague, T. Roques, K. Spencer, A. Burnett, J. Lourenco, N. Thorp
The success and safety of modern radiotherapy relies on accurate contouring. Understanding the time taken to complete radiotherapy contours is critical to informing workforce planning and, in the context of a workforce shortfall, advocating for investment in technology and multi-professional skills mix. We aimed to quantify the time taken to delineate target volumes for radical radiotherapy. The Royal
-
A Randomised Phase II Trial to Evaluate the Feasibility of Radiotherapy Dose Escalation, Facilitated by Intensity-Modulated Arc Radiotherapy Techniques, in High-Risk Neuroblastoma Clin. Oncol. (IF 3.4) Pub Date : 2024-03-15 J.E. Gains, A. Patel, Yen-Ch’ing Chang, H.C. Mandeville, G. Smyth, C. Stacey, J. Talbot, K. Wheatley, M.N. Gaze
-
Radiomics for clinical decision support in radiation oncology Clin. Oncol. (IF 3.4) Pub Date : 2024-03-15 L. Russo, D. Charles-Davies, S. Bottazzi, E. Sala, L. Boldrini
Radiomics is a promising tool for the development of quantitative biomarkers to support clinical decision-making. It has been shown to improve the prediction of response to treatment and outcome in different settings, particularly in the field of radiation oncology by optimising the dose delivery solutions and reducing the rate of radiation-induced side effects, leading to a fully personalised approach
-
High-dose-rate Brachytherapy Monotherapy in Patients With Localised Prostate Cancer: Dose Modelling and Optimisation Using Computer Algorithms Clin. Oncol. (IF 3.4) Pub Date : 2024-03-14 K. Dabic-Stankovic, K. Rajkovic, J. Stankovic, G. Marosevic, G. Kolarevic, B. Pavicar
Interstitial high-dose-rate brachytherapy (HDR-BT) is an effective therapy modality for patients with localized prostate carcinoma. The objectives of the study were to optimise the therapy regime variables using two models: response surface methodology (RSM) and artificial neural network (ANN). Thirty-one studies with 5651 patients were included (2078 patients presented as low-risk, 3077 patients with
-
Volumetric Response and Survival of Patients With Bulky IDH-Mutated Grade 3 Glioma Managed With FET-FDG–Guided Integrated Boost IMRT Clin. Oncol. (IF 3.4) Pub Date : 2024-03-13 D. Mills, P. Horsley, V. Venkatasha, M. Back
Despite relatively favourable outcomes associated with IDH-mutant grade 3 gliomas, many patients present with diffuse non-enhancing disease involving multiple brain regions, prompting concern over both durable disease control and the morbidity associated with large volume radiation therapy. This study audits volumetric response, survival and functional outcomes in this ‘large volume’ subgroup that
-
National Survey of Current Follow-up Protocols for Patients Treated for Endometrial Cancer in the UK Clin. Oncol. (IF 3.4) Pub Date : 2024-03-13 H. Patel, K. Drinkwater, A. Stewart
The aim of this study was to establish a baseline of national practice for follow-up after treatment for endometrial cancer in the UK. An online cross-sectional survey was developed and distributed through the Royal College of Radiologists via an email link to the audit leads of radiotherapy centres in the UK. The survey was conducted from November 2021 to 5 January 2022. The main themes assessed in
-
OncoFlash – Research Updates in a Flash! (April 2024 Edition) Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 M. Denholm, C. Crockett
-
Audit of Outcomes from Bone Biopsies in Patients with Suspected or Progressive Metastatic Breast Cancer Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 A. Young, D. Roi, S. Cleator
-
Interstitial Lung Disease Associated with Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer: a Real-world Experience Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 A. Shaheen, H. Hayhurst, O. Omokhodion, A. Ayyad
-
Real-world Data Collection of Toxicity Data from Patients on Everolimus and Exemestane in a Large UK Tertiary Oncology Centre Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 S. Raby, F. Coe, V. Misra
-
The Prognostic Value of Low HER2 Expression on Treatment Outcomes in Metastatic Hormone Receptor-positive Breast Cancer Patients Treated with CDK4/6 Inhibitors and Endocrine Therapy Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 R. Muhammad, S. Mumtaz, N. Goyal, A. Konstantis
-
Comparison of Target Volume Coverage and Organs at Risk in Contoured Regional Nodes versus a Field-based Approach in Adjuvant Breast Radiotherapy Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 C. Guo, C. Kane, A. Anderson, M. Lovegrove, S. Needleman
-
NICE Technology Appraisals in Breast Oncology and the Impact on Cancer Treatment Unit Activity at the Sussex Cancer Network – 10-year Update Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 K. Eremeishvili, R. Simcock, P. Savage
-
Incidence and Management of Transtuzumab Emtansine- and Transtuzumab Deruxetecan-related Pneumonitis in Breast Cancer Patients within Leicester Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 S. Bhagani, O. Akala
-
Assessing Agreement to the Use of Hormone Replacement Therapy for Breast Cancer Patients Experiencing Menopausal Symptoms Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 A. Ali, A. Branson, P. Bradley
-
Gut Microbiota Predict Efficacy of Neoadjuvant Systemic Therapy in Patients with Early Breast Cancer Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 K. Ross, B. Nichols, R. Papadopoulou, M. Macleod, J. Fraser, S. Barrett, K. Teo, E. Mallon, A. Ammar, J. Edwards, J. Evans, K. Gerasimidis, I. Macpherson
-
Audit of Hypersensitivity Reactions (HSRs) of Patients with Breast Cancer being Treated with Nab-paclitaxel after Severe HSR to Prior Taxane Chemotherapy; is it Safe? Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 M. Jaschke, X. Ren, C. Michie
-
Estimated Absolute Risks from Typical UK Radiotherapy for Early Breast Cancer During 2015–2023 Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 F. Holt, A. Ivanova, N. Roberts, Z. Wang, D. Dodwell, C. Taylor
-
Interventions for Managing Late Gastrointestinal Symptoms Following Pelvic Radiotherapy: a Systematic Review and Meta-analysis Clin. Oncol. (IF 3.4) Pub Date : 2024-02-19 H. Berntsson, A. Thien, D. Hind, L. Stewart, M. Mahzabin, W.S. Tung, M. Bradburn, M. Kurien
Pelvic radiotherapy can induce gastrointestinal injury and symptoms, which can affect quality of life. We assessed interventions for managing these symptoms. A review of randomised controlled trials published between January 1990 and June 2023 from databases including MEDLINE, EMBASE, CENTRAL, CINAHL, , ISRCTN and grey literature sources was conducted. Meta-analyses were carried out using the DerSimonian
-
Oral Cavity Cancers: Ethnic Differences in Radiotherapy Outcomes in a Majority South Asian Leicester Community Clin. Oncol. (IF 3.4) Pub Date : 2024-02-15 N. Patil, N. Ma, M. Mair, J. Nazareth, A. Sim, C. Reynolds, N. Freeman, M. Chauhan, L. Howells, D. Peel, S. Ahmad, T. Sridhar, H.S. Walter
Squamous cell carcinoma oral cavity cancers (SCCOCCs) have a higher reported incidence in South Asian countries. We sought to compare presenting stage and outcome by ethnicity in patients with SCCOCC treated with radical radiotherapy in a single centre in the UK. All patients with SCCOCC treated with radical radiotherapy at an oncology department in Leicester (UK) between 2011 and 2017 were identified
-
Pharyngeal Constrictor Muscle Sparing in Head and Neck Radiotherapy Clin. Oncol. (IF 3.4) Pub Date : 2024-02-15 K. Oguejiofor, C.S. Boon, S. Ramkumar, I.S. Boon
-
OncoFlash–Research Updates in a Flash! (Mar 2024) Clin. Oncol. (IF 3.4) Pub Date : 2024-02-14 A. Chowdhury, C. Lorimer
-
-
-
NLRP3 Inflammasome: A Potential Therapeutic Target in Head and Neck Cancers Clin. Oncol. (IF 3.4) Pub Date : 2024-02-12 S. Sekaran, S. Warrier, V. Selvaraj, D. Ganapathy, P. Ramasamy
-
The UK Divide: Does Having a Pembrolizumab–Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab–Chemotherapy Combination in Scotland Clin. Oncol. (IF 3.4) Pub Date : 2024-02-12 A. Thapa, A. Cowell, A. Peters, D.J. Noble, A. James, C. Lamb, D. Grose, S. Vohra, S. Schipani, K. Mactier, J. Mackenzie, D. Srinivasan, K. Laws, R. Moleron, P. Niblock, F.-Y. Soh, C. Paterson, C. Wilson
The Scottish Medical Consortium recently approved first-line pembrolizumab monotherapy or in combination with chemotherapy for head and neck squamous cell carcinoma in the palliative setting, contrasting with the decision made by the National Institute for Health and Care Excellence, who approved monotherapy alone in England and Wales. The aim of this study was to provide real-world performance data
-
National Institute for Health and Care Excellence and Royal College of Radiologists' Fractionation Guideline for Metastatic Spinal Cord Compression Clin. Oncol. (IF 3.4) Pub Date : 2024-02-12 J.S. Lim, C.S. Boon, K. Oguejiofor, S. Ramkumar, I.S. Boon
-
The Increasing Role of Genomics Testing in Thyroid Cancers Clin. Oncol. (IF 3.4) Pub Date : 2024-02-12 I.S. Boon
-
Contralateral Nodal Relapse in Well-lateralised Oral Cavity Cancers Treated Uniformly with Ipsilateral Surgery and Adjuvant Radiotherapy With or Without Concurrent Chemotherapy: a Retrospective Study Clin. Oncol. (IF 3.4) Pub Date : 2024-02-10 M. Swain, A. Budrukkar, V. Murthy, P. Pai, A. Kanoja, S. Ghosh-Laskar, A. Deshmukh, G. Pantvaidya, S. Kannan, V.M. Patil, V. Naronha, K. Prabhash, S. Sinha, A. Kumar, T. Gupta, J. Agarwal
To evaluate the incidence and pattern of contralateral nodal relapse (CLNR), contralateral nodal relapse-free survival (CLNRFS) and risk factors predicting CLNR in well-lateralised oral cavity cancers (OCC) treated with unilateral surgery and adjuvant ipsilateral radiotherapy with or without concurrent chemotherapy. Consecutive patients of well-lateralised OCC treated between 2012 and 2017 were included
-
Predicting Survival with Brain Metastases in the Stereotactic Radiosurgery Era: are Existing Prognostic Scores Still Relevant? Or Can we do Better? Clin. Oncol. (IF 3.4) Pub Date : 2024-02-09 M.W. Fittall, M. Brewer, J. de Boisanger, L. Kviat, A. Babiker, H. Taylor, F. Saran, J. Konadu, F. Solda, A. Creak, L.C. Welsh, N. Rosenfelder
Predicting survival is essential to tailoring treatment for patients diagnosed with brain metastases. We have evaluated the performance of widely used, validated prognostic scoring systems (Graded Prognostic Assessment and diagnosis-specific Graded Prognostic Assessment) in over 1000 ‘real-world’ patients treated with stereotactic radiosurgery to the brain, selected according to National Health Service
-
Prehabilitation for Patients with Cancer Undergoing Radiation Therapy: a Scoping Review Clin. Oncol. (IF 3.4) Pub Date : 2024-02-08 E. Harris, L. Marignol
Prehabilitation is a process of identifying and assessing factors that could compromise the physical and psychological health of patients undergoing cancer treatment and implementing an intervention to combat such concerns. The use of prehabilitation in cancer surgery has yielded positive outcomes in rectal, lung and abdominal cancers. Prehabilitation strategies have potential to improve the management
-
Quality of Decision Making in Radiation Oncology Clin. Oncol. (IF 3.4) Pub Date : 2024-02-06 S.K. Vinod, R. Merie, S. Harden
High-quality decision making in radiation oncology requires the careful consideration of multiple factors. In addition to the evidence-based indications for curative or palliative radiotherapy, this article explores how, in routine clinical practice, we also need to account for many other factors when making high-quality decisions. Foremost are patient-related factors, including preference, and the
-
The National Radiotherapy Trials Quality Assurance Group – Driving up Quality in Clinical Research and Clinical Care Clin. Oncol. (IF 3.4) Pub Date : 2024-02-02 E. Miles, J. Wadsley, P. Diez, R. Patel, S. Gwynne
Abstract not available
-
Quality of Radiotherapy Workforce Training within the USA Clin. Oncol. (IF 3.4) Pub Date : 2024-02-02 R. Mulherkar, D.C. Ling, R. Tendulkar, M.R. Kamrava, S. Beriwal
The training, competency requirements and scope of practice of professionals within a radiation oncology department vary across countries. The purpose of this review is to shed light on the current status of radiotherapy training in the USA by discussing current benchmarks for medical residency, physics residency, radiation therapy and dosimetry training programmes. Although there are notable strengths
-
Clinicopathological Profile and Survival Outcomes in Patients with Localised Extremity Synovial Sarcomas Clin. Oncol. (IF 3.4) Pub Date : 2024-02-01 J. Sharma, S.V.S. Deo, S. Kumar, A.W. Barwad, S. Rastogi, D.N. Sharma, G. Singh, S. Bhoriwal, A. Mishra, R. K, J. Saikia, A. Mandal, B. Bansal, M. Gaur
Synovial sarcoma is a rare but aggressive variant of soft-tissue sarcoma. Literature is sparse and reported mostly from the West. We analysed the clinical profiles and prognostic factors of extremity synovial sarcoma patients in order to study their clinical journey. This was a retrospective analysis. All patients with extremity synovial sarcoma treated between 1992 and 2020 were included. Patients
-
Efficacy and Safety of Preoperative Transcatheter Rectal Arterial Chemoembolisation in Patients with Locally Advanced Rectal Cancer: Results from a Prospective, Phase II PCAR Trial Clin. Oncol. (IF 3.4) Pub Date : 2024-01-29 Weina Yang, Chengyuan Qian, Jiamin Luo, Chuan Chen, Yan Feng, Nan Dai, Xuemei Li, Xiao He, Yuxin Yang, Mengxia Li, Chunxue Li, Dong Wang
Aims The PCAR study aimed to assess the efficacy and safety of preoperative transcatheter rectal arterial chemoembolisation (TRACE) in patients with locally advanced rectal cancer (LARC). Materials and methods This was a single-centre, prospective, phase II trial conducted in China. Eligible patients were adults aged 18 years and older with histologically confirmed stage II or III rectal carcinoma
-
Big Data and Colorectal Cancer: The Revolution will be Personalised Clin. Oncol. (IF 3.4) Pub Date : 2024-01-23 Christopher J.M. Williams, Jenny F. Seligmann
Abstract not available
-
Trends and Variation in the Use of Radiotherapy in Non-metastatic Rectal Cancer: a 14-year Nationwide Overview from the Netherlands Clin. Oncol. (IF 3.4) Pub Date : 2024-01-20 A.-S.E. Verrijssen, J. Evers, M. van der Sangen, S. Siesling, M.J. Aarts, H. Struikmans, M.C.W.M. Bloemers, J. Burger, V. Lemmens, P. Braam, M. Elferink, M. Berbee
Aims This study describes nationwide primary radiotherapy utilisation trends for non-metastasised rectal cancer in the Netherlands between 2008 and 2021. In 2014, both colorectal cancer screening and a new guideline specifying prognostic risk groups for neoadjuvant treatment were implemented. Materials and methods Patients with non-metastasised rectal cancer in 2008–2021 (n = 37 510) were selected
-
Evaluation of Delivered Doses in Proton Beam Therapy for Prostate Cancer Using Positron Emission Tomography/Computed Tomography Imaging Clin. Oncol. (IF 3.4) Pub Date : 2024-01-19 S. Shiraishi, M. Yamanaka, T. Murai, K. Tokuuye
Aims Proton beams deposit energy along their paths and stop abruptly without penetrating the opposite side, making it difficult to detect their actual paths. However, confirming the path may lead to evaluating the actual doses to organs at risk in proton therapy for prostate cancer. As proton beams produce positron emitters through nuclear fragmentation reactions, theoretically, proton beam paths can
-
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Surveillance Strategies in Patients with Stage I, II, III or Resectable IV Melanoma Who Were Treated with Curative Intent Clin. Oncol. (IF 3.4) Pub Date : 2024-01-20 S. Rajagopal, X. Yao, W. Abadir, T.D. Baetz, A.M. Easson, G. Knight, E. McWhirter, C. Nessim, C.F. Rosen, A. Sun, F.C. Wright, T.M. Petrella
To make recommendations on managing the surveillance of patients with stage I, II, III or resectable IV melanoma who are clinically free of disease following treatment with curative intent. This guideline was developed by Ontario Health's (Cancer Care Ontario's) Program in Evidence-Based Care and the Melanoma Disease Site Group (including seven medical oncologists, four surgical oncologists, three
-
Improved Dosimetry with Daily Online Adaptive Radiotherapy for Cervical Cancer: Waltzing the Pear Clin. Oncol. (IF 3.4) Pub Date : 2024-01-17 A. Yen, Xinran Zhong, Mu-Han Lin, C. Nwachukwu, K. Albuquerque, B. Hrycushko
Aims Standard of care radiotherapy for locally advanced cervical cancer includes large margins to ensure the uterocervix remains within the treatment fields over the course of treatment. Daily online cone-beam adaptive radiotherapy corrects for interfractional changes by adjusting the plan to match the target position during each treatment session, thus allowing for significantly reduced clinical target